Navigation Links
Experimental insulin-like growth factor receptor inhibitor reduced pancreatic cancer growth
Date:4/14/2009

PHILADELPHIA Researchers at Amgen are testing a fully human monoclonal antibody that inhibits the activity of insulin-like growth factors (IGF-1 and IGF-2) and appears to reduce pancreatic cancer cells in early testing, according to a report in Molecular Cancer Therapeutics, a journal of the American Association for Cancer Research.

Pancreatic cancer is one of the deadliest cancers, and less than 4 percent of the 200,000 patients diagnosed annually live more than five years. The only available clinical treatment is gemcitabine, but this has yet to show a survival benefit.

Scientists are testing a variety of experimental therapies to bring pancreatic cancer under control. At Amgen, Pedro J. Beltran, Ph.D., a principal scientist in oncology research, is experimenting with AMG 479, a fully human anti-IGF-1 monoclonal antibody.

"We know that insulin-like growth factors play a role in cancer development, particularly in mediating cell survival. This is the first drug that specifically targets the receptor for these growth factors without cross-reacting with the closely related insulin receptor," said Beltran.

In the in vitro study, AMG 479 bound to IGF-1R and blocked both IGF-1 and IGF-2 binding factors 1 and 2. It also completely inhibited ligand-induced activation in some growth factors, which led to a decreased cellular viability. When Beltram and colleagues measured the effect of AMG 479 on pancreatic cancer cells in vivo, the inhibition rate was approximately 80 percent inhibition of tumor growth and receptor expression was observed.

"These data clearly show that AMG 479 is a clinical candidate for pancreatic cancer therapy, either alone or in combination with gemcitabine," he said.

Beltran said researchers are currently testing AMG 479 in nine separate phase II studies of various cancer types; he expects the effect will be seen beyond pancreatic cancer.


'/>"/>

Contact: Jeremy Moore
Jeremy.moore@aacr.org
267-646-0557
American Association for Cancer Research
Source:Eurekalert

Page: 1

Related medicine news :

1. Experimental anti-cancer drug made from corn lillies kills brain tumor stem cells
2. Experimental Antidepressants Offer Faster Relief
3. Experimental drug shows promise in advanced kidney cancer
4. Experimental drug boosts survival in recurrent ovarian cancer
5. Experimental cancer pharmaceuticals under trial
6. Experimental Drug Fails Against Heart Failure
7. Experimental Drug Fights Prostate Cancer
8. Experimental technique at GUMC offers real-time analysis of breast cancer biopsies
9. Experimental Vaccine Halts Prostate Cancer in Mice
10. Experimental Biology 2008 Todays Research: Tomorrows Health, April 5-9
11. 52 minority scientists receive travel fellowships to Experimental Biology 2008
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/3/2016)... ... ... With the opioid epidemic now at the forefront, attention has shifted away from ... its misuse causes long-term consequences for all aspects of society, from the disastrous effects ... and older. In addition, there is the long term affects of chronic liver ...
(Date:5/3/2016)... Santa Monica, California (PRWEB) , ... May 03, 2016 , ... ... cosmetic surgery practice in late 2014, incorporating the injectable filler into his menu ... journeys of aesthetic transformation. Now, more than a year later, he’s still improving his ...
(Date:5/3/2016)... ... May 03, 2016 , ... Diagnotes, ... by Tidelands Health, a three hospital system in South Carolina, to provide its ... lookout for technology that enhances communication, drives workflow efficiencies and improves provider and ...
(Date:5/3/2016)... (PRWEB) , ... May 03, 2016 , ... Park Cities ... live in or adjacent to the 75204, 75205, 75206, 75209, 75219, 75220, 75225, 75229, ... Greenway Parks, Bluffview, Midway Hollow, North Dallas, Plano, Preston Hollow and Park Cities areas ...
(Date:5/3/2016)... Corner, VA (PRWEB) , ... May 03, 2016 ... ... leading provider of innovative information technology (IT) solutions and digital consulting services to ... Enterprise Information Technology Services (EITS) Indefinite Delivery / Indefinite Quantity (ID/IQ) contract in ...
Breaking Medicine News(10 mins):
(Date:5/2/2016)... 2, 2016  While nearly three-quarters of Americans (71%) ... on their health, only about half report taking any ... results of a new survey announced today by Hologic ... of National Osteoporosis Month, Hologic is raising awareness of ... 56 million Americans. Osteoporosis is a disease ...
(Date:5/2/2016)... 2, 2016 The global  ... 11.1 billion by 2024, according to a new ... drivers of the sonography market include expanding applications ... recommendations for periodic ultrasound screenings of the breast ... http://photos.prnewswire.com/prnh/20150105/723757 ) High Intensity Focused ...
(Date:4/29/2016)... , April 29, 2016 ... Review, H1 2016" market research report that provides ... with comparative analysis at various stages, therapeutics assessment ... of administration (RoA) and molecule type, along with ... It also reviews key players involved in the ...
Breaking Medicine Technology: